Targeted Oncology1d
What's Next for Frontline Metastatic RCC Therapy
Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...
Ocean Biomedical announces findings in EGFR-mutant lung cancer
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
The American Journal of Managed Care12h
Deucravacitinib Shows Long-Term Safety, Efficacy in Psoriasis Trial
A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.
The American Journal of Managed Care5d
Discontinuing Versus Switching BTK Inhibitors for Toxicity
Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...
New blood-clotting disorder identified
Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...
EurekAlert!2d
Dana-Farber researchers present findings at 2025 ASCO Genitourinary Cancers Symposium
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...
Becker's Hospital Review2d
A spoonful of innovation: Karmanos pioneers at-home liver cancer treatment
TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...
Too Old to Operate10d
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...